Ocrelizumab (2) – Ocrevus®
Relapsing-remitting multiple sclerosis, aged ≥ 10 to < 18 years
Characteristics
| Start date | 15.11.2026 |
|---|---|
| Resolution | 05.05.2027 – active procedure |
| INN | Ocrelizumab |
| Brand name | Ocrevus® |
| Pharm. company | Roche Pharma AG |
| G-BA Procedure ID | D-1401 |
| Therapeutic area | n.d. |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Ocrelizumab (2) | Ocrevus® | Roche Pharma AG | Relapsing-remitting multiple sclerosis, aged ≥ 10 to < 18 years | n.d. | active procedure | |
| Ocrelizumab (1) | Ocrevus® | Roche Pharma AG | Multiple sclerosis (MS) | 165,300–182,200 | 81% Proof of minor additional benefit |
<< List of all resolutions